HIGHLIGHTS
- What: Instead, the authors provide a summary of response rates and event-free survival (EFS) of pexidartinib-treated patients. Given the very low rate of response in this small study population it is reasonable to include that short-term exposure to pexidartinib did not enhance response to paclitaxel in patients with high-risk early-stage HER2-negative breast cancer.
- Who: Hope S. Rugo from the University of California San Francisco, Box, San Francisco, CA, USA have published the article: Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.